Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.356 | Circulating Bacterial-Derived DNA Fragments and Markers of Iinflammation in Peritoneal Dialysis Patients | Prof. SZETO Cheuk Chun |
| 2024.381 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.429 | A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) | Prof. SZETO Cheuk Chun |
| 2024.402 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.609 | Systemic Absorption of Oral Vancomycin Used for the Treatment of Clostridioides Difficile-Associated Diarrhea |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.178 | The Efficacy and Safety of Intermittent Sodium Zirconium Cyclosilicate Therapy for the Prevention of Hyperkalemia in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2024.321 | Defining the optimal frequency of dialysis adequacy test for peritoneal dialysis patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.136 | Acute kidney injury in acute coronary syndrome: prevalence, risk factors, and prognosis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.315 | Discontinuation of sodium-glucose cotransporter-2 inhibitors in advanced chronic kidney disease |
Professor Szeto Cheuk Chun 司徒卓俊 |
| 2020.224 | Optimal Strategy for the Monitoring of Dialysis Adequacy in Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.245 | Defining the Optimal Duration of Treatment for “Low-Risk” Peritoneal Dialysis-Related Peritonitis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.363 | Intra-renal miR-21 expression in IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2020.643 | The Efficacy and Safety of SGLT2 Therapy in Advanced Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.646 | Regulation of Peritoneal Transport by the Cyclooxygenase Pathway and Its Pharmacological Modulation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.283 | The role of Activating Transcription Factor 5 (ATF5) for mitochondrial protection in diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.582 | Pharmacological Treatment of Mitochondrial Dysfunction in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2020.601 | Optimization of Urine Processing for Biomarker Development of Kidney Diseases |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.483 | Cost-effectiveness analysis of screening of BK virus-associated nephropathy using urine cytology and serum quantitative polymerase chain reaction |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.480 | Urinary RNA Levels as Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.482 | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | Prof. SZETO Cheuk Chun |
| 2014.352 | Long Non-Coding RNA (IncRNA) in the Urinary Sediment of Patients with Chronic Kidney Disease | Professor SZETO Cheuk Chun |
| 2017.648 | Extracellular Mitochondrial DNA Released by Peritoneal Mesothelial Cell as the Trigger of Macrophage Activation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2017.368 | Urinary Sediment RNA Profile for the Prediction of Therapeutic Response in Lupus Nephritis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.564 | Urinary Podocyte mRNA as a Prognostic Marker of Diabetic Nephropathy | Prof. SZETO Cheuk Chun |
| 2016.721 | Urinary Mitochondrial DNA Level as a Biomarker of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.327 | The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients with High Dialysis Effluent Bacterial DNA Fragment Levels |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.228 | Relation Between Peritoneal Dialysis Effluent microRNA Level and Longitudinal Change in Peritoneal Transport Characteristics |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.250 | Genetic Determinants of Peritoneal Transport Characteristics and Cardiovascular Diseases for Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2017.420 | Urinary miRNA profile as the biomarker of IgA nephropathy |
Prof Szeto Cheuk Chun 司徒卓俊 |
| 2013.532 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients | Professor SZETO Cheuk Chun |
| 2013.564 | A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis | Prof. SZETO Cheuk Chun |
| 2014.242 | Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients | Professor Szeto Cheuk Chun |
| 2010.164 | TRK-100STP Phase Iib/III Clinical Study Protocol | Prof. SZETO Cheuk Chun |
| 2010.278 | Hemoglobin Variability in Chinese Pre-Dialysis CKD Patients Not Reciving Erythropoietin | Prof. SZETO Cheuk Chun |
| 2009.355 | The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition | Prof. SZETO Cheuk Chun |
| 2021.738 | Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊教授 |
| 2022.159 | Optimization of Peritoneal Dialysis Prescription by Early Determination of Peritoneal Transport Characteristics |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.170 | Development of a novel risk score for the prognosis of IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.163 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2022.684 | SGLT2 Inhibitor and DPP-4 Inhibitor for Podocyte Protection in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.740 | Fluid Overload as the Cause of Gut Permeability Barrier Dysfunction in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2022.206 | The Relation Between Glycemic Variability on Renal Mitochondrial Injury in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.641 | Peritoneal Leukocyte Load as Predictor of Peritoneal Membrane Failure |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.020 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.562 | Urinary Biomarkers for the Early Diagnosis and Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.363 | Modified Creatinine Index as a Non-Invasive Tool for the Monitoring of Muscle Mass in Peritoneal Dialysis |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2022.125 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2023.247 | A multicentered, single-group Phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with Immunoglobulin A nephropathy (IgAN) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
Page 65 of 262.